The Long-Awaited ‘Mass Effect' Show Has a Showrunner Now
Prime Video's upcoming Mass Effect show is progressing slowly, but surely. On Friday, Deadline revealed the live-action series gained Doug Jung as its showrunner.
Jung, who most may remember as the co-writer for 2016's Star Trek Beyond, recently ended a showrunner/executive producer stint for Apple TV+'s Chief of War. He'll be working alongside writer Dan Casey, and both will EP for the series alongside franchise producer Mike Gamble. As Deadline notes, this is a 'major step forward' in the show's development, which was first teased all the way back in 2021, then had its existence reaffirmed back in 2024.
To date, Prime Video's kept mum on what exactly Casey's pitch was for the Mass Effect show. Among fans, the general thinking is that it'll just adapt the initial trilogy of Commander Shepard gathering allies to fight the Reapers. (This also seemed to be the plan when a movie seemed likely back in 2007 after the first game came out.) But shows like Castlevania and Prime Video's own Fallout have taken a different approach that tells an original story inside the worlds of those series. (Fallout in particular carries itself like a Fallout 5 we're getting to watch but not play.) Others, like Tomb Raider and Dragon Age, continued (or hoped to) the stories of the games they're based on.
There's certainly different routes for the Mass Effect series to take, and we'll be interested to learn Jung and Casey's approach in due time.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
PGA Tour Sends Strong Scottie Scheffler Message on Saturday
PGA Tour Sends Strong Scottie Scheffler Message on Saturday originally appeared on Athlon Sports. The PGA Tour celebrated Scottie Scheffler in style on Saturday, honoring the world No. 1 golfer on his birthday with an Instagram post from @pgatour showcasing his top 10 career shots. Advertisement The post, shared earlier today, serves as a tribute to his remarkable journey, timed perfectly as fans and the Tour alike mark his special day. This gesture underscores Scheffler's status as a golfing icon and the Tour's commitment to celebrating its brightest stars. The post highlights iconic moments, including his hole-in-one at the 2023 Charles Schwab Challenge and his remarkable eagle hole-out at the 2024 Players Championship. These shots reflect the precision and power that have defined his rise, with three wins in his last five starts this season, including a victory at the 2025 PGA Championship. Scottie Scheffler plays his shot from the tenth tee during the first round.© Charles LeClaire-Imagn Images The birthday tribute aligns with Scheffler being in contention at the Travelers Championship this weekend, tying for the 36-hole lead with a score of nine under par. Advertisement This celebration sends a clear message: Scheffler, at 29, is the Tour's present and future and will continue to dominate a majority of the tournaments he plays in. With competitors like Tommy Fleetwood and Justin Thomas challenging his lead, his career highlights remind fans of his consistency and clutch performances. The post has sparked excitement, reinforcing the Tour's intent to honor excellence while hyping its toughest course setups and merit-based finales. For golf enthusiasts, it's a fitting birthday salute to a player redefining the sport. Related: PGA Tour Teases Scottie Scheffler, Justin Thomas Pairing at Travelers Championship This story was originally reported by Athlon Sports on Jun 21, 2025, where it first appeared.
Yahoo
30 minutes ago
- Yahoo
Owen Wilson will return for ‘Meet The Parents 4'
Owen Wilson will return for 'Meet The Parents 4', alongside Ben Stiller, Robert De Niro and Ariana Grande.
